Pasadena, CA (PRWEB) June 06, 2011
Neumedicines, a privately held drug discovery and development company focused on innovative protein therapies for the treatment of hematopoietic deficiencies, cancer and autoimmune diseases, announced today that a profile of the company and its pipeline of oncology and hematology drug candidates is featured in the most recent issue of BioWorld, one of the most widely read publications in the pharma and biotech industries. The article can be purchased at http://www.bioworld.com.
The publication noted that, “Seizing opportunity from the failure of others, Neumedicines Inc. is breathing new life into Interleukin-12 (IL-12), a biologic once seen as the great hope for cancer. The Pasadena, Calif.-based company launched a Phase I safety trial Thursday for its lead candidate, HemaMax™, a key regulator of the hematopoietic system. Initially, the trial will enroll about 40 subjects, but Neumedicines plans to expand its safety database to cover up to 500 volunteers from diverse populations.”
The article also noted: “Neumedicines has big plans for its lead candidate. The company is working on the protocol for a Phase I cancer study with the START Center in San Antonio and hopes to file an investigational new drug application in the fall for pancreatic cancer.”
Dr. Lena Basile, Neumedicines Chief Executive Officer said, “We are pleased to receive recognition from a global biotech publication for our lead pipeline product, HemaMax™, that has demonstrated robust and broad hematopoietic recovery in lethally irradiated animal models as well as in tumor-bearing animals treated with radiation and chemotherapy.”
“We look forward to the results of our Phase I HemaMax™ clinical trial which we expect by February 2012,” Dr. Basile added.
About BioWorld Today®
BioWorld® Today, the news source of record for the biotechnology industry, is read by biotechnology professionals worldwide for its hard-hitting, objective news reporting. BioWorld Today is delivered via e-mail every business morning, and is also found exclusively online at http://www.bioworld.com. The BioWorld online web site has been internationally recognized as the most comprehensive resource for strategic biotechnology news and information available today.
About Neumedicines Inc.
Neumedicines Inc. is a privately held, early-stage company developing protein therapeutics that address unmet clinical and societal needs in the fields of oncology, hematology, and immunology. The company’s lead product candidate, NMIL12-1 (recombinant human interleukin-12; rHuIL-12), functions as to target multiple pathways of hematopoiesis and innate immunity and is being developed to address a range of clinical indications. At Neumedicines, we are committed to developing and maximizing the scientific, clinical, and commercial potential of our product pipeline.
Neumedicines is developing NMIL12-1 under the trade name HemaMax™ as a biodefense radiation medical countermeasure. NMIL12-1 is also being developed for indications in hematology/oncology, such as chemotherapy-induced thrombocytopenia. The company operates from its headquarters and laboratories in Pasadena, California.
For more information visit: http://www.neumedicines.com
Follow Neumedicines on Twitter @Neumedicines
This press release contains certain forward-looking statements relating to our business. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs. There can be no assurance that any product in Neumedicines pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.
Investor and partnership inquires please contact: Dr. Lena Basile at 626-844-3800 or basile(at)neumedicines(dot)com
Media members please contact: Jeff Richardson at 805-491-8313 or jeff(at)richardsonglobalpr(dot)com
# # #